
Henry Schein (HSIC) Stock Forecast & Price Target
Henry Schein (HSIC) Analyst Ratings
Bulls say
Henry Schein Inc. demonstrated robust revenue growth across its key segments, with medical products revenue increasing by 4.7% as reported and 3.0% on a local internal basis, while dental business revenue rose by 2.7%. The global technology segment also experienced significant expansion, generating $173 million in revenue with a growth rate of 9.7% as reported and 9.0% on a local internal basis. Additionally, the forecast for adjusted EBITDA in 2025 suggests a mid-single-digit growth, reflecting the company's strong operational performance and positive outlook for future earnings.
Bears say
Henry Schein Inc. experienced a significant decline in profitability, with a gross margin of 31.4% that fell 110 basis points year-over-year and missed expectations by 60 basis points. The company's US dental merchandise revenue decreased by 1.2%, attributed to pricing pressure, while international merchandise revenue showed only marginal growth of 1.9% but also suffered a local internal decline. Consequently, adjusted EBITDA projections for fiscal year 2025 have been reduced to $1.090 billion, indicating a potential slowdown in growth and highlighting the challenges faced in maintaining profitability amidst competitive pricing pressures.
This aggregate rating is based on analysts' research of Henry Schein and is not a guaranteed prediction by Public.com or investment advice.
Henry Schein (HSIC) Analyst Forecast & Price Prediction
Start investing in Henry Schein (HSIC)
Order type
Buy in
Order amount
Est. shares
0 shares